CPE
VC Fund
Beijing, China
CPE is a leading alternative asset manager, with asset classes spanning private equity, mezzanine and the public market. Founded in 2008 by a world class team of investment professionals and supported by over 200 domestic and international investors, CPE knows China like no one else and is a globally minded long-term value investor. The firm usesits sector expertise to generate deal flow and drive the value creation work during the post-investment stage. CPE follows a disciplined investment approach to preserve and grow its investors’ capital. The firm’s private equity portfolio of more than 100 companies is highly diversified by sector and stage of investment. CPE takes pride in its forward-looking investment philosophy and works hard to create value over the long-term for its investors and a better world. For more information, please visit www.citicpe.com.
- Total investments:
- 108
- Last investment:
- Lead investor:
- 37%
- Fund size:
- $70M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries CPE invests in
Stages CPE invests in
Countries CPE invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
3 more contacts available
Round size
- Series A
- $2.8M–$1B
- Series B
- $12M–$286M
- Series C
- $42M–$400M
Investment Focus
Industry
- Manufacturing 19 (18%)
- Health Care 18 (17%)
- Biotechnology 16 (15%)
- Artificial Intelligence 15 (14%)
- Medical 10 (9%)
Stage
- Series A 20 (19%)
- Series B 16 (15%)
- Series C 14 (13%)
- Series D 13 (12%)
- Private Equity 12 (11%)
Country
- China 89 (82%)
- United States 5 (5%)
- Israel 1 (1%)
- Hong Kong 1 (1%)
- United Kingdom 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anton Boisen
Founder
|
Founder | Total investments: 0 | Find email | |
|
beibei hou
Principal
|
Principal | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
ModelBest
|
Mianbi Smart enables large-scale model acceleration and application execution using artificial intelligence. | Venture - Series Unknown / Feb 28, 2026 | |
Orange Connex Global UK Limited
|
Orange Connex Global UK Limited is a technology-led fourth-party logistics provider (4PL) to enable global supply chains. | Private Equity / Jan 01, 2024 | |
Sangon Biotech
|
Sangon Biotech Co. (生工生物) is engaged in the research and development of chemical synthesis of DNA.It is a high-tech Sino-foreign joint venture established in 2003. After ten years of development, Sangon has become a professional biotechnology company that integrates research and development. Chemical synthesis DNA earned reputation for Sangonin the global market.In 2006, Sangon invested 50 million to build a manufacturing and industrial base in Songjiang Industrial Park, which has been put into use. Sangon produces various products such as DNA synthesis, DNA sequencing, Gene Synthesis, peptide synthesis, chemical agents, enzymes, molecular biology kit, cultivation medium, lab consumptive material, and miniature instruments. | $290.4M / Venture - Series Unknown / Apr 19, 2023 | |
Royma
|
Royma is a high-tech R&D and production enterprise integrating R&D, production, sales and service. | Series A / Apr 17, 2023 | |
Jinyuansheng
|
Jinyuansheng is mainly engaged in the development, smelting and deep processing of new energy key metal mineral resources. | $148.3M / Series B / Aug 14, 2022 | |
Enflame
|
Suiyuan Technology is a provider of neural network solutions for artificial intelligence. Its products are deep learning high-end chips developed for cloud data centers, and are positioned on artificial intelligence training platforms. The chip will adopt a unique and innovative architecture independently developed, featuring high computing power,high energy efficiency ratio, programmable, low cost, and support for mainstream machine learning frameworks. It is designed and optimized for cloud AI training. | Series C / Aug 10, 2022 | |
Reliable Med
|
Reliable Med is a medical device developer. | $15M / Series A / Mar 31, 2022 | |
XVERSE
|
XVERSE develops artificial intelligence models and 3D content platforms that enable digital and virtual interactions. | $120M / Series A / Mar 11, 2022 | |
SiBionics
|
SiBionics is a medtech specialized in R&D & commercialization of implantable medical devices and medical imaging artificial intelligence. | $126M / Series C / Jan 21, 2022 | |
Lumous Intelligence
|
Lumous is a leading brand of smart hotel solutions, providing integrated solutions to help hotels streamline the operational processes, optimize service quality and curate personalized guest experiences. Lumous Intelligence was founded in 2018 and was headquartered in Shanghai, China. | Series B / Dec 22, 2021 | |
| See all 108 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does CPE invest in?
CPE invests primarily in Manufacturing, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 108 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is CPE's check size?
CPE typically joins rounds of $2.8M–$1B at Series A, $12M–$286M at Series B and $42M–$400M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds CPE participates in.
How do I contact CPE?
Public channels for CPE include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CPE?
The team at CPE includes Anton Boisen (Founder) and beibei hou (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
